|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
1,518,000 |
Market
Cap: |
10.23(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$5.2 - $16.52 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Kala Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization of therapies for diseases of the eye. Co.'s two marketed products are EYSUVIS® (loteprednol etabonate ophthalmic suspension) 0.25%, for the short-term (up to two weeks) treatment of the signs and symptoms of dry eye disease, and INVELTYS® (loteprednol etabonate ophthalmic suspension) 1%, a topical twice-a-day ocular steroid for the treatment of post-operative inflammation and pain following ocular surgery. Co. is also progressing its pipeline of proprietary programs targeted to address front and back of the eye diseases, including KPI-287 and glucocorticoid receptor modulators.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
13,504 |
24,904 |
24,904 |
44,341 |
Total Sell Value |
$82,239 |
$159,016 |
$159,016 |
$166,208 |
Total People Sold |
5 |
6 |
6 |
6 |
Total Sell Transactions |
5 |
11 |
11 |
16 |
End Date |
2024-03-07 |
2023-12-05 |
2023-06-06 |
2022-06-06 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Isaly Samuel D |
10% Owner |
|
2018-01-12 |
4 |
B |
$15.40 |
$438,068 |
I/I |
28,446 |
2,692,715 |
1.5 |
- |
|
Isaly Samuel D |
10% Owner |
|
2018-01-11 |
4 |
B |
$13.65 |
$569,205 |
I/I |
41,700 |
2,664,269 |
1.5 |
- |
|
Isaly Samuel D |
10% Owner |
|
2018-01-10 |
4 |
B |
$12.83 |
$2,185,437 |
I/I |
170,338 |
2,622,569 |
1.5 |
- |
|
Brazzell Kim |
Chief Medical Officer |
|
2017-08-11 |
4 |
OE |
$0.68 |
$178,039 |
D/D |
108,725 |
108,725 |
|
- |
|
Isaly Samuel D |
See Remarks |
|
2017-07-25 |
4 |
B |
$15.00 |
$4,789,995 |
I/I |
319,333 |
2,375,279 |
1.5 |
- |
|
Isaly Samuel D |
See Remarks |
|
2017-07-25 |
4 |
A |
$0.00 |
$0 |
I/I |
2,055,946 |
2,055,946 |
|
- |
|
Longitude Venture Partners Ii, L.p. |
10% Owner |
|
2017-07-25 |
4 |
B |
$15.00 |
$3,225,000 |
I/I |
215,000 |
2,270,946 |
1.5 |
- |
|
Longitude Venture Partners Ii, L.p. |
10% Owner |
|
2017-07-25 |
4 |
A |
$0.00 |
$0 |
I/I |
2,055,946 |
2,055,946 |
|
- |
|
Kolchinsky Peter |
former 10% owner |
|
2017-07-25 |
4 |
B |
$15.00 |
$7,999,995 |
I/I |
533,333 |
2,113,236 |
0.01 |
- |
|
Kolchinsky Peter |
former 10% owner |
|
2017-07-25 |
4 |
A |
$0.00 |
$0 |
I/I |
1,579,903 |
1,579,903 |
|
- |
|
Paull Robert Bradley |
Director |
|
2017-07-25 |
4 |
A |
$0.00 |
$0 |
I/I |
1,204,937 |
1,204,937 |
|
- |
|
Tepper Robert I |
Director |
|
2017-07-25 |
4 |
A |
$0.00 |
$0 |
I/I |
1,621,092 |
1,621,092 |
|
- |
|
Grunberg Gregory |
Director |
|
2017-07-25 |
4 |
B |
$15.00 |
$3,225,000 |
I/I |
215,000 |
2,270,946 |
2.1 |
- |
|
Grunberg Gregory |
Director |
|
2017-07-25 |
4 |
A |
$0.00 |
$0 |
I/I |
2,055,946 |
2,055,946 |
|
- |
|
Shah Rajeev M. |
Director |
|
2017-07-25 |
4 |
B |
$15.00 |
$7,999,995 |
I/I |
533,333 |
2,113,236 |
2.1 |
- |
|
Shah Rajeev M. |
Director |
|
2017-07-25 |
4 |
A |
$0.00 |
$0 |
I/I |
1,579,903 |
1,579,903 |
|
- |
|
Hadley Harbor Master Investors (cayman) L.p. |
10% Owner |
|
2017-07-25 |
4 |
A |
$0.00 |
$0 |
D/D |
1,735,460 |
846,566 |
|
- |
|
Kovner Bruce |
10% Owner |
|
2017-07-20 |
4/A |
B |
$15.00 |
$3,225,000 |
D/D |
215,000 |
763,755 |
2.45 |
- |
|
Kovner Bruce |
10% Owner |
|
2017-07-20 |
4/A |
A |
$0.00 |
$0 |
D/D |
548,755 |
548,755 |
|
- |
|
Kovner Bruce |
10% Owner |
|
2017-07-20 |
4 |
B |
$15.00 |
$3,225,000 |
D/D |
215,000 |
215,000 |
2.45 |
- |
|
Langer Robert |
Director |
|
2017-07-19 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
326,402 |
|
- |
|
Rosen Howard B |
Director |
|
2017-07-19 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
3,240 |
|
- |
|
Chen Hongming |
Chief Scientific OfficerOffice |
|
2017-07-19 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
46,080 |
|
- |
|
Hanes Justin |
10% Owner |
|
2017-07-19 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
601,923 |
|
- |
|
149 Records found
|
|
Page 6 of 6 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|